At two years, Gilead lymphoma therapy active in 40 percent of patients

Nearly 40 percent of lymphoma patients treated with a single infusion of Gilead Sciences Inc’s Yescarta continued to respond to the cell therapy after at least two years of follow up, the company said on Sunday.